Combination therapy for recurrent ovarian cancer
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests a new combination of chemotherapy, immunotherapy, and a bladder relaxant for ovarian cancer that has come back after initial treatment. It aims to see if adding these drugs together can help control the cancer longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have ovarian, fallopian tube, or primary peritoneal cancer that has come back after initial treatment.
- Your last treatment included a platinum-based chemotherapy, and it has been less than 12 months since that treatment ended.
- You are able to do daily activities without help (ECOG score 0 or 1).
- You have not had prior treatment with certain immunotherapies (like PD-1 or PD-L1 inhibitors).
- You are willing to provide a tumor tissue sample from a past surgery or a new biopsy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination treatment for ovarian cancer that has come back after earlier treatment. It aims to see if the combination can shrink tumors or slow the disease, and it may be an option for people whose cancer has become resistant to platinum-based chemotherapy.
This trial tests a combination of three drugs — liposomal irinotecan (a type of chemotherapy), sintilimab (an immunotherapy that helps your immune system fight cancer), and anlotinib (a targeted therapy that blocks blood vessels feeding the tumor) — for women with ovarian clear cell carcinoma that has returned or not responded to standard treatment. The goal is to see if this combination can shrink or control the cancer better than existing options.
This trial tests a new targeted drug, SHR-A1811, combined with chemotherapy for women whose ovarian cancer has returned but still responds to platinum-based drugs. The goal is to see if the combination works better than chemotherapy alone.
This study tests a combination of two drugs (trastuzumab rezetecan and bevacizumab) for women with ovarian cancer that has returned after initial treatment. The goal is to see if this combination helps control the cancer longer.
This trial tests a new combination of treatments for advanced ovarian, fallopian tube, or peritoneal cancer. It combines chemotherapy and immunotherapy (drugs that help your immune system fight cancer) with a special vaccine made from your own tumor. The goal is to see if this approach is more effective than standard treatment.
This trial is testing a new drug, LBL-024, combined with chemotherapy (with or without a targeted therapy called bevacizumab) for ovarian cancer that has stopped responding to standard platinum-based treatment. The goal is to see if this combination can effectively shrink tumors and slow the disease's progression.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.